Literature DB >> 10096577

AIDS-associated Kaposi's sarcoma is more aggressive in women: a study of 54 patients.

G Nasti1, D Serraino, A Ridolfo, A Antinori, G Rizzardini, C Zeroli, L Nigro, M Tavio, E Vaccher, U Tirelli.   

Abstract

OBJECTIVE: To describe the epidemiologic and clinical features of AIDS-associated Kaposi's sarcoma (KS) in women compared with men.
METHODS: In a retrospective study, within the Italian Cooperative Group on AIDS and Tumors (GICAT), we compared selected characteristics of 54 women and 108 men with AIDS-associated KS, matched by date of KS diagnosis and referral hospital. The chi2 test was used to test differences among proportions; the Kaplan-Meier method to estimate the survival time, and the Cox proportional hazard model was used to assess the role of gender, age, and CD4 cell count on death's risk.
RESULTS: KS occurred at an earlier age (p = .001), was associated with a more severe immunodeficiency (p = .03), more advanced stages of HIV disease (p = .05), and had more aggressive presentation and course in women than in men. At KS diagnosis, women had a significantly increased proportion of visceral disease (p = .009), in particular pulmonary involvement (p = .002) and atypical sites of involvement (p = .008). The number of deaths due to KS was significantly higher (p = .01) in female patients. Both the higher proportion of visceral disease and of KS-related deaths observed in women did not change after adjusting for CD4 cell count and age. Women showed a decreased overall survival compared with men (8.9 and 14.4 months, respectively; p = .07), and the CD4 cell count at diagnosis significantly influenced survival.
CONCLUSIONS: This study suggests that KS is more aggressive and life threatening in female than in male patients. This peculiar clinical behavior may reflect an inherently more aggressive biology of KS in women, possibly mediated by the level of immunodeficiency.

Entities:  

Mesh:

Year:  1999        PMID: 10096577     DOI: 10.1097/00042560-199904010-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  10 in total

1.  Evaluation of a Predictive Staging Model for HIV-Associated Kaposi Sarcoma in Uganda.

Authors:  Fred Okuku; Elizabeth M Krantz; James Kafeero; Moses R Kamya; Jackson Orem; Corey Casper; Warren Phipps
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731

2.  A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.

Authors:  Anisa Mosam; Fahmida Shaik; Thomas S Uldrick; Tonya Esterhuizen; Gerald H Friedland; David T Scadden; Jamila Aboobaker; Hoosen M Coovadia
Journal:  J Acquir Immune Defic Syndr       Date:  2012-06-01       Impact factor: 3.731

3.  Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.

Authors:  Julia Bohlius; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Daniela Garone; Mazvita Sengayi; Matthew P Fox; Mary-Ann Davies; Matthias Egger
Journal:  Int J Cancer       Date:  2014-05-02       Impact factor: 7.396

4.  Oral HHV-8 replication among women in Mombasa, Kenya.

Authors:  Warren Phipps; Misty Saracino; Stacy Selke; Meei-Li Huang; Walter Jaoko; Kishorchandra Mandaliya; Anna Wald; Corey Casper; R Scott McClelland
Journal:  J Med Virol       Date:  2014-04-01       Impact factor: 2.327

Review 5.  Regulation of sex hormone receptors in sexual dimorphism of human cancers.

Authors:  Daoshan Zheng; Cecilia Williams; Jeremy A Vold; Justin H Nguyen; Denise M Harnois; Sanjay P Bagaria; Sarah A McLaughlin; Zhaoyu Li
Journal:  Cancer Lett       Date:  2018-09-14       Impact factor: 8.679

6.  Sex Differences in HIV: Natural History, Pharmacokinetics, and Drug Toxicity.

Authors:  Obiamiwe C Umeh; Judith S Currier
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.663

7.  Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda.

Authors:  Warren Phipps; Fred Ssewankambo; Huong Nguyen; Misty Saracino; Anna Wald; Lawrence Corey; Jackson Orem; Andrew Kambugu; Corey Casper
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

8.  Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.

Authors:  Michael E Herce; Noel Kalanga; Emily B Wroe; James W Keck; Felix Chingoli; Listern Tengatenga; Satish Gopal; Atupere Phiri; Bright Mailosi; Junior Bazile; Jason A Beste; Shekinah N Elmore; Jonathan T Crocker; Jonas Rigodon
Journal:  J Int AIDS Soc       Date:  2015-05-29       Impact factor: 5.396

9.  Oral HIV-Associated Kaposi Sarcoma: A Clinical Study from the Ga-Rankuwa Area, South Africa.

Authors:  Razia A G Khammissa; Liron Pantanowitz; Liviu Feller
Journal:  AIDS Res Treat       Date:  2012-09-12

10.  Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy.

Authors:  Mulinda Nyirenda; McNeil Ngongondo; Minhee Kang; Triin Umbleja; Susan E Krown; Catherine Godfrey; Wadzanai Samaneka; Rosie Mngqibisa; Brenda Hoagland; Noluthando Mwelase; Stephanie Caruso; Oto Martinez-Maza; Dirk P Dittmer; Margaret Borok; Mina C Hosseinipour; Thomas B Campbell
Journal:  J Acquir Immune Defic Syndr       Date:  2020-08-01       Impact factor: 3.771

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.